Replies to post #328725 on Amarin Corp Plc (AMRN)

[HDGabor]

H-

This is a flawed analysis on many levels.

As I wrote

My layman view

Furthermore, my approach is neutral ... meanwhile "there may very well be a direct deleterious effect of" something for other ones.

Best,
G

[ralphey]

HK ...

I have about 15 patients trigs >500 that failed vascepa - (dont go under 500)

Can go to fibrates but cant use with statins
Could use gemfibrozil but a lot of side effects
So by default I end up with lovaza and then add a statin

[dukesking]

HK, Great post. I hope this is something payers will figure out and make the appropriate change to the language that caps the REDUCEIT indication to trigs <500. If they adhere to this language, it suggests that they could deny any script for Vascepa once your trigs drop below <150. That suggests that Vascepa is being treated as a lipid modulator not a CVD treatment. It also suggest that a patient that has severe CVD risk, and initial trigs <150, would be denied Vascepa. UHC decision is a huge step in the right direction but needs refining or at least language that allows the doctor to treat the patient not the trigs.